PORT VILA, Vanuatu, June 11, 2026 /CNW/ — Vantage, a global multi-asset broker for CFD trading, announced its inclusion on the Fortune Crypto Innovators list. Selected independently by Fortune’s editorial department based on its editorial criteria, the list serves as a recognised industry reference point, highlighting companies operating within the digital asset and broader financial ecosystems.

As traditional finance and digital assets continue to converge, navigating the operational and technological complexities of both landscapes requires robust infrastructure. Vantage’s selection highlights its capacity to provide access to both sectors, positioning the broker alongside prominent crypto-native businesses and institutional financial participants featured on the list.

Marc Despallieres, Chief Executive Officer at Vantage, commented: “Securing a position on Fortune Crypto Innovators list is a significant milestone that reflects our long-term commitment to operational development and product innovation. In an evolving market landscape, our objective remains providing clients with a functional and transparent trading ecosystem. This recognition from Fortune provides an independent acknowledgement of our global infrastructure and continued development.”

The Fortune Crypto Innovators list provides an independent assessment based on Fortune’s editorial criteria. As one of the few multi-asset CFD platforms included in the list, this recognition highlights Vantage’s ability to connect traditional financial markets–including forex, commodities, and indices–with the evolving digital asset landscape through a single, multi-asset trading platform.

Fortune’s long-standing reputation in global business rankings gives this recognition additional relevance for companies operating at the intersection of finance, technology, and digital assets. This recognition provides an independent third-party acknowledgement of Vantage’s continuous corporate development and operational capabilities within the multi-asset sector.

Looking forward, as global financial markets become increasingly interconnected, the demand for sophisticated multi-asset brokerage solutions continues to evolve. Vantage remains focused on investing in its core platform infrastructure, risk management tools, and multi-asset liquidity pools to maintain a reliable environment for market participants globally. This ongoing development allows Vantage to support access to a broad range of markets for global participants navigating changing market conditions.

To learn more about the platform and its inclusion in the Fortune Crypto Innovators list, visit Vantage Markets.

About Vantage

Vantage Markets is a multi-asset CFD broker offering access to Forex, Commodities, Indices, Shares, ETFs, and Bonds. With over 16 years of experience, Vantage provides a reliable trading platform, an award-winning mobile app, and a user-friendly trading experience.

Risk Warning: CFDs are complex instruments and carry a high risk of losing money rapidly due to leverage. Ensure you understand the risks before trading.

Disclaimer: This content is for informational purposes only and does not constitute financial or investment advice. It is not directed at residents of jurisdictions where CFD trading is restricted or prohibited.

View original content to download multimedia:https://www.prnewswire.com/news-releases/vantage-secures-position-on-the-fortune-crypto-innovators-list-highlighting-cross-market-trading-innovation-302798755.html

SOURCE Vantage

SHANGHAI, June 12, 2026 /PRNewswire/ — GCL System Integration Technology Co., Ltd. (“GCL SI” or “the Company”) has showcased its scenario-based PV solutions at the SNEC 2026 which was held in Shanghai, China from June 3 to 5. GCL SI showcased a comprehensive multi-matrix product portfolio, including high-efficiency TOPCon and BC modules, scenario-based component solutions, and mobile green energy systems. The exhibition highlighted the Company’s latest achievements across four strategic dimensions: high-efficiency cells, scenario-based solutions, mobile energy, and ecosystem development.

Advancing Application-Specific Solar Deployment

The photovoltaic industry is evolving from scale-driven growth toward value creation through more precise and differentiated applications. To address this shift, GCL SI showcased five scenario-specific module solutions: anti-dust modules for commercial and industrial applications, anti-glare modules for airports and highways, high-efficiency modules for utility-scale ground-mounted projects, steel-frame modules for 2,000V desert PV applications, and composite-frame modules for marine environments. Covering land, sea, high altitude, typhoon zones, and corrosive environments, this scenario-based approach is designed to address the varying performance, reliability and economic requirements of different deployment environments.

For extreme wind and high‑altitude environments, GCL SI’s steel-frame modules offer twice the tear resistance of traditional aluminum frames, withstanding extreme wind conditions of up to 60 m/s in typhoon-prone regions while improving overall project economics compared with conventional aluminum-frame designs. For harsh high-salt, high-humidity and high-heat offshore conditions, the marine-specific modules feature double-coated glass, high-water-resistance encapsulants, and full-structure protection, passing top-level salt spray and rigorous reliability tests to solve corrosion, hot spot, and aging challenges.  In the commercial and industrial distributed PV market, the S-series anti-dust modules combine high-density encapsulation, full-screen anti-dust design, and advanced sealing for enhanced reliability.

GCL SI’s focus on product quality and reliability was further validated by its designation as a 2026 Kiwa-PVEL TOP PERFORMER, one of the photovoltaic industry’s most widely recognized benchmarks for module performance and reliability.

Digitalization Supporting Low-Carbon Value Creation

GCL SI, together with Ant Digital Technologies, launched “GCL Carbon Chain 3.0” at SNEC 2026 and initiated the Carbon Chain 4.0 roadmap.

Leveraging GCL SI’s deep industry expertise in PV manufacturing, supply chain management, and low-carbon product innovation, and supported by Ant Digital’s blockchain, AI and digital technologies, Carbon Chain 3.0 establishes a product carbon footprint monitoring and verification mechanism. The platform integrates carbon footprint management across procurement, manufacturing and delivery processes, enhancing transparency and supporting low-carbon value creation throughout the supply chain. Additionally, GCL SI has enhanced its integrated “module + green certificate” service capability, offering green asset solutions for both domestic and international markets.

GCL SI is also translating its application-driven strategy into international markets through targeted partnerships. In Africa, the company is collaborating with PowerChina Guiyang Engineering Corporation to develop off-grid integrated solar-storage solutions. In Latin America, GCL SI is deepening its strategic partnership with Coexito to strengthen channel presence and brand positioning.

On the ecosystem front, GCL SI is working with Ant Digital Technologies and Digital China to advance digital energy ecosystem development, integrating blockchain, AI, and data governance to build a smarter, more connected clean energy future.

Looking ahead, GCL SI believes the next phase of solar industry growth will be driven by solutions that deliver superior performance, sustainability, and application-specific value. The company will continue to advance technologies that support the evolving needs of global energy markets.

SOURCE GCL SI

BURLINGAME, Calif., June 11, 2026 /PRNewswire/ — Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics, today announced that it has priced its previously announced upsized underwritten public offering of 8,933,334 shares of its common stock at a price to the public of $37.50 per share and, in lieu of common stock to investors who so choose, pre-funded warrants to purchase up to 1,733,333 shares of Enliven’s common stock at a price to the public of $37.499 per pre-funded warrant, which represents the per share public offering price of each share of Enliven’s common stock less the $0.001 per share exercise price for each pre-funded warrant. All of the shares and pre-funded warrants are being sold by Enliven. The gross proceeds from the offering are expected to be approximately $400.0 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about June 15, 2026, subject to the satisfaction of customary closing conditions. In addition, Enliven has granted the underwriters a 30-day option to purchase up to an additional 1,600,000 shares of its common stock at the public offering price, less the underwriting discounts and commissions.

Jefferies, Goldman Sachs & Co. LLC, Morgan Stanley and Barclays are acting as joint book-running managers for the offering. Mizuho is also acting as a book-running manager and LifeSci Capital is acting as a passive book-running manager for the offering. Baird is acting as lead manager and Jones is acting as manager for the offering.

The offering is being made pursuant to a Registration Statement on Form S-3ASR, including a base prospectus, which became automatically effective upon filing with the U.S. Securities and Exchange Commission (SEC) on August 13, 2025, and Enliven has filed with the SEC a preliminary prospectus supplement and accompanying prospectus relating to the offering. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed for free through the SEC’s website at www.sec.gov. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at (866) 471-2526, or by email at Prospectus-ny@ny.email.gs.com; Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, or by email at prospectus@morganstanley.com; or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email at barclaysprospectus@broadridge.com.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation, or sale would be unlawful before registration or qualification under the securities laws of any such state or jurisdiction.

About Enliven Therapeutics 
Enliven is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics to help people not only live longer, but live better. Enliven aims to address existing and emerging unmet needs with a precision medicine approach that improves survival and enhances overall well-being. Enliven’s discovery process combines deep insights in clinically validated biological targets and differentiated chemistry to design potentially first-in-class or best-in-class therapies. Enliven is based in Burlingame, California.

Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements about Enliven within the meaning of the federal securities laws, including those related to the timing of the closing of the offering and the expected gross proceeds. These forward-looking statements are neither promises nor guarantees and are subject to a variety of risks and uncertainties, including but not limited to: the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Information regarding the foregoing and additional risks may be found in the section entitled “Risk Factors” in documents that Enliven files from time to time with the Securities and Exchange Commission, including the registration statement and the preliminary prospectus supplement relating to the public offering. These forward-looking statements are made as of the date of this press release, and Enliven assumes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

View original content to download multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-announces-pricing-of-upsized-public-offering-of-common-stock-and-pre-funded-warrants-302798760.html

SOURCE Enliven Therapeutics, Inc.